5 completed, 2 terminated, 1 recruiting, 1 unknown. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow von Hippel-Lindau Disease: new trials by email Literature Review of von Hippel-Lindau Disease trials Research Report on von Hippel-Lindau Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors Oral HS-10516 - Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 60 | 2024-07-19 | 2024-08-14 |
| A Study of BPI-452080 in Subjects With Solid Tumors BPI-452080 - Solid Tumor, Renal Cell Carcinoma | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 87 | 2023-04-28 | 2023-05-06 |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies DFF332, RAD001, PDR001 - Carcinoma, Renal Cell | Phase 1 | Terminated | Novartis Pharmaceuticals | 40 | 2021-11-30 | 2026-03-03 |
| A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab, E10030 - Von Hippel-Lindau Syndrome | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 3 | 2017-01-23 | 2021-11-01 |
| Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) Vorinostat - Von Hippel-Lindau Disease | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 7 | 2014-04-05 | 2018-09-14 |
| Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome Sunitinib Malate - Von Hippel-Lindau Syndrome | Phase 1 / Phase 2 | Terminated | National Eye Institute (NEI) | 2 | 2008-05-01 | 2024-01-05 |
| Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy ranibizumab injection (0.5 mg) - Coats' Disease, Idiopathic Retinal Telangiectasia | Phase 1 / Phase 2 | Completed | Manhattan Eye, Ear & Throat Hospital | 18 | 2007-05-01 | 2012-10-25 |
| Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Ranibizumab - Von Hippel-Lindau Syndrome | Phase 1 | Completed | National Eye Institute (NEI) | 5 | 2004-08-10 | 2017-07-02 |
| EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome EYE001 - Hippel-Lindau Disease | Phase 1 | Completed | National Eye Institute (NEI) | 5 | 2003-03-01 | 2008-03-04 |
Carcinoma, Renal Cell (2) · Macular Edema (2) · Hemangioblastoma (1) · Hereditary leiomyomatosis and renal cell cancer (1) · Myopia, Degenerative (1) · Neoplasms (1) · Neuroectodermal Tumors, Primitive (1) · Optic Nerve Neoplasms (1) · Paraganglioma (1) · Pheochromocytoma (1) · Polypoidal Choroidal Vasculopathy (1) · Pseudoxanthoma Elasticum (1) · Retinal Telangiectasis (1) · Vision Disorders (1)
Abnormalities, Multiple (9) · Angiomatosis (9) · Cardiovascular Diseases (9) · Ciliopathies (9) · Congenital Abnormalities (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Genetic Diseases, Inborn (9) · Nervous System Diseases (9) · Neurocutaneous Syndromes (9) · Vascular Diseases (9) · Neoplasms (5) · Neoplasms by Histologic Type (4) · Eye Diseases (3) · Macular Degeneration (3) · Neoplasms by Site (3)
Ranibizumab (3) · E10030 aptamer (1) · Everolimus (1) · Sunitinib (1) · Vorinostat (1) · spartalizumab (1)
National Eye Institute (NEI) (4) · Betta Pharmaceuticals Co., Ltd. (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Manhattan Eye, Ear & Throat Hospital (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Novartis Pharmaceuticals (1)
United States (7) · China (2) · Czechia (1) · France (1) · Italy (1) · Japan (1) · Singapore (1) · Spain (1)
Catherine Meyerle, MD (1) · Dingwei Ye, Ph.D (1) · Henry E Wiley, M.D. (1) · Jian Zhang, Ph.D (1) · Kan Gong, PhD (1) · Lawrence A. Yannuzzi, MD (1) · Prashant Chittiboina, M.D. (1)